Alpha-enolase (ENO1) is a metabolic enzyme involved in the synthesis of pyruvate. It also acts as a plasminogen receptor and mediates the activation of plasmin and extracellular matrix degradation. In tumor cells, ENO1 is up-regulated and supports the Warburg effect; it is expressed at the cell surface, where it promotes cancer invasion, and is subjected to a specific array of post-translational modifications, namely acetylation, methylation and phosphorylation. ENO1 overexpression and post-translational modifications could be of diagnostic and prognostic value in many cancer types. Information on the biochemical, proteomics and immunological characterization of ENO1, and particularly its ability to trigger a strong specific humoral and cellular immune response, make this ubiquitous protein an interesting tumor target; DNA vaccination with ENO1 in preclinical models efficiently delays the development of very aggressive tumors such as pancreatic cancer. This review aims to analyze the main stages by which the tumor associated antigen (TAA) ENO1 has become a promising target that opens potential avenues for cancer immunotherapy.

Alpha-Enolase (ENO1), a potential target in novel immunotherapies

CAPPELLO, Paola
First
;
PRINCIPE, MOITZA;BULFAMANTE, SARA;NOVELLI, Francesco
2017

Abstract

Alpha-enolase (ENO1) is a metabolic enzyme involved in the synthesis of pyruvate. It also acts as a plasminogen receptor and mediates the activation of plasmin and extracellular matrix degradation. In tumor cells, ENO1 is up-regulated and supports the Warburg effect; it is expressed at the cell surface, where it promotes cancer invasion, and is subjected to a specific array of post-translational modifications, namely acetylation, methylation and phosphorylation. ENO1 overexpression and post-translational modifications could be of diagnostic and prognostic value in many cancer types. Information on the biochemical, proteomics and immunological characterization of ENO1, and particularly its ability to trigger a strong specific humoral and cellular immune response, make this ubiquitous protein an interesting tumor target; DNA vaccination with ENO1 in preclinical models efficiently delays the development of very aggressive tumors such as pancreatic cancer. This review aims to analyze the main stages by which the tumor associated antigen (TAA) ENO1 has become a promising target that opens potential avenues for cancer immunotherapy.
22
5
944
959
https://www.bioscience.org/fbs/getfile.php?FileName=/2017/v22/af/4526/4526.pdf
Alpha-enolase; ENO1; Cancer; Humoral Response; Glycolysis; Invasion; Immunotherapy; Pancreatic Cancer; Plasminogen Receptor; T cell response; Vaccination; TAAs; Metastasis; Review
Cappello Paola; Principe Moitza; Bulfamante Sara; Novelli Francesco
File in questo prodotto:
File Dimensione Formato  
Cappello_front biosci_2017.pdf

Accesso aperto

Descrizione: post-print
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 795.29 kB
Formato Adobe PDF
795.29 kB Adobe PDF Visualizza/Apri
Cappello P et la, Frontiers 2017.pdf

Accesso riservato

Descrizione: Cappello P et al, Front biasci 2017
Tipo di file: PDF EDITORIALE
Dimensione 726.16 kB
Formato Adobe PDF
726.16 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1632372
Citazioni
  • ???jsp.display-item.citation.pmc??? 40
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 51
social impact